clindamycin + levofloxacin + meropenem

This is a combination of three antibiotics—clindamycin, levofloxacin, and meropenem—used together for the treatment of severe or resistant bacterial infections.

• Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is particularly effective against Gram-positive cocci and anaerobes, and is sometimes used for toxin suppression in toxin-mediated diseases such as necrotizing fasciitis.
• Levofloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. It has broad-spectrum activity against both Gram-negative and Gram-positive bacteria.
• Meropenem is a carbapenem β-lactam antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs). It has very broad-spectrum activity including many multidrug-resistant organisms.

This triple combination may be considered in critically ill patients with suspected or confirmed polymicrobial infections (including those caused by resistant organisms), especially when broad empiric coverage—including anaerobic bacteria—is required. The use of all three agents together would be rare outside highly specific clinical scenarios due to overlapping spectra; however, combinations like these are sometimes used in severe sepsis/sept­ic shock or life-threatening intra-abdominal infections where maximal initial coverage is desired before narrowing therapy based on culture results.